Cargando…
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers – a new active regimen
Irinotecan, mitomycin and cisplatin all demonstrate activity in gastro-oesophageal cancers. This novel combination was administered to outpatients with previously untreated inoperable gastro-oesophageal or pancreatic cancer, in a 28-day cycle. A total of 26 out of 31 patients with gastro-oesophageal...
Autores principales: | Slater, S, Shamash, J, Wilson, P, Gallagher, C J, Slevin, M L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376181/ https://www.ncbi.nlm.nih.gov/pubmed/12373598 http://dx.doi.org/10.1038/sj.bjc.6600553 |
Ejemplares similares
-
Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer
por: Crumley, A B C, et al.
Publicado: (2006) -
The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
por: Powles, Thomas, et al.
Publicado: (2008) -
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
por: Yarchoan, Mark, et al.
Publicado: (2017) -
Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial
por: Michel, P, et al.
Publicado: (2006) -
Definitive chemoradiation in patients with inoperable oesophageal carcinoma
por: Crosby, T D L, et al.
Publicado: (2004)